Pricing Log in Create free account
Friday 6 November 2026 Export ALNY’s income statement to Excel — free account

Alnylam Pharmaceuticals, Inc.

ALNY Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.

Revenue
+16.7%
EPS
+747.6%
Free cash flow
−4.76%
Total debt
−2.66%

Quarter to September 2026, against a year earlier

156.50 0.16 −0.10%
Market cap
$21.0B
P/E
7.9×
Fwd P/E
13.5×
Dividend yield
—
F-score
6/9
Altman Z
7.30
Beneish M
−1.95
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Alnylam Pharmaceuticals, Inc. 8-K filed May 27, 2026

Period ended May 20, 2026 · Filed · accepted 4:30 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov